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doi:10.1016/j.jmii.2010.08.006Background: Pneumocystis jirovecii pneumonia (PJP) remains the leading cause of opportu-
nistic infections and deaths among human immunodeficiency virus (HIV)-infected patients.
We would like to identify the predictors of mortality of these patients at initial presentation,
and assist clinicians to aware the patients in risk of mortality earlier.
Methods: From 1997 to 2009, adults with HIV infection and a discharge diagnosis of PJP at
Mackay Memorial Hospital were included in this retrospective study. Patients’ demographic
data and laboratory data were analyzed by reviewing the medical records.
Results: Eighty-five patients were included in this study. The overall mortality rate was 37.7%.
Univariate analysis revealed several host factors significantly related to mortality, including
age, systolic blood pressure, diastolic blood pressure, partial pressure of oxygen in arterial
blood (PaO2), percentage of lymphocyte, percentage of CD4 lymphocyte, CD4 counts, serum
total protein, serum albumin, and blood urea nitrogen. Multivariate analysis identified three
independent predictors associated with mortality, i.e. systolic blood pressure 110 mmHg
[adjusted odds ratio (AOR) 3.88; 95% confidence interval (CI) 1.17e12.83; p Z 0.03], PaO2
at room air 60 mmHg (AOR 4.97; 95% CI 1.34e18.23; p Z 0.01), and lymphocytes 10%
(AOR 8.19; 95% CI 1.48e45.36; p Z 0.02). With these predictors, we can stratify patients into
three groups with increasing risks for mortality, one predictor (mortality rate 14%), any two
predictors (47%), and three predictors (75%).nfectious Disease, Department of Medicine, Mackay Memorial Hospital, No. 92, Section 2, Chungshan
l.com (C.-M. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Predictors of mortality in HIV-infected PJP patients 275Conclusions: HIV-infected patients with PJP can be clinically stratified by three prognostic
variables identified by multivariate analysis. Early recognition of patients in higher risk can
assist clinicians to prevent rapid deterioration and seek for better outcomes.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Pneumocystis jiroveciipneumonia (PJP) (previously known as
Pneumocystis carinii), is a common opportunistic infection
for hospitalization of patients with acquired immunodefi-
ciency syndromes (AIDS), and is often life threatening.1e4 The
mortality rate for human immunodeficiency virus (HIV)-
infected patient with PJP ranged from 11 to 53% in recent
studies.1,5e9 Because of high-mortality rate, experts take
effort to determine events affecting mortality earlier for
providing better care and outcomes in hospital.
Several factors associated with mortality from HIV-
infected PJP patients have been identified previously,
including age of the patient,3,6,10 poor oxygenation at
admission to hospital [based on partial pressure of oxygen in
the arteries (PaO2) at roomair or alveolar-arterial O2 (A-a O2)
gradient],1,3,10 septic shock requiring vasopressor use,11,12
low-hemoglobin level,3 low-total leukocyte count,12 low-
serum albumin level,1,9,10,13 higher total bilirubin level,10
need for mechanical ventilation support,6,9,11,13 develop-
ment of pneumothorax,6,9 wasting,1 higher acute physiology
and chronic health evaluation II score,12 number of acute
respiratory failure causes,11 recent injection drug use,10
pulmonary Kaposi sarcoma,3 and acute kidney injury
requiring renal replacement therapy.12 Among these factors,
some could not be quantitated precisely, such as wasting,
vasopressor use, or severity of pneumothorax; some would
be too complicated to be required, such as acute physiology
and chronic health evaluation II score, renal replacement
therapy, or pulmonary Kaposi sarcoma. Because of these
limitations, clinicians need a simple tool for stratifying HIV-
infected patients with PJP by risk for mortality at illness
presentation.
Therefore, we performed a retrospective study of HIV-
infected adult patients with diagnosis of PJP in a tertiary
care center of northern Taiwan more than 13-year period.
We collected clinical and laboratory data from these
patients at or soon after their admission, and our goals
were to measure the mortality rate in our study group; to
compare differences between mortality and survival
subgroups; to identify objectively independent predictors
of mortality; and to develop a predicting rule that could
stratify patients by the risk for mortality.
Methods
Patients who were discharged with diagnosis of HIV-related
diseases between 1 January 1997 and 31 December 2009 at
Mackey Memorial Hospital, a 2,100-bed tertiary care center
in northern Taiwan, were reviewed in this study. We con-
ducted a computerized search of hospital records by the
International Classification of Diseases, 9th revision (ICD-9)
codes, and 304 adult patients with 440 admissions werescreened because of diagnosis of HIV infection. Their
medical records were carefully reviewed. Readmission at
more than 2 weeks after discharge was considered as
another admission. A definitive PJP was diagnosed by iden-
tification of Pneumocystis cystic or trophic forms on micro-
scopic examination of Giemsa-stained induced sputum or
bronchoalveolar lavage (BAL) specimens. Presumptive
diagnosis was dependent on a history of recent onset (within
the past 3 months) of dyspnea on exertion or nonproductive
cough, image studies [including high-resolution computed
tomography (HRCT) scan] with typical findings such as
diffuse pattern of ground-glass opacity, and no evidence
of a bacterial pneumonia or concurrent opportunistic
infections.
Data collection
The patients’ medical records were retrospectively
reviewed. Clinical data abstraction included: demographic
characteristics; medical history; HIV and noneHIV-related
comorbid conditions; cigarette, alcohol, anddrugusehistory;
preadmission use of antiretroviral and prophylactic medica-
tions; CD4 counts, CD8 counts, and plasma HIV viral load titer
within 1 month of admission; and initial vital signs, arterial
blood gas, and the initial laboratory data at presentation.
Highly active antiretroviral therapy (HAART) was defined
as use of at least three antiretroviral agents fromat least two
classes among the following: protease inhibitors, nucleoside
reverse transcriptase inhibitors, and nonnucleoside reverse
transcriptase inhibitors. We defined patients as receiving
HAART if the medication was prescribed for more than 30
days before admission. Mortality was defined as death in the
hospital or discharged at critical condition. Prior pulmonary
diseases were defined as a history of physician-diagnosed
nonmalignant lung diseases, such as pulmonary tuberculosis,
chronic bronchitis/emphysema, or asthma. Recent injection
drug use was defined as injection during the 6 months before
admission.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) for Windows (Version
12.0; SPSS Inc., Chicago, IL, USA). Results are reported as
numbers and percentages. Continuous variables were
analyzed by means, standard deviations (SDs), medians, and
ranges. Independent sample t test was used to check the
association between clinical characteristics and mortality. A
p value of<0.05 was considered statistically significant, and
two-tailed test was adopted for all probabilities. Univariate
and multivariate analyses were performed using logistic
regression with mortality as the dependent variable.
Predictors with nonnormal distribution were dichotomized
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relevant values. We considered all predictors with p value
<0.05 in univariate analysis for inclusion in the multivariate
model.
Results
Forty-five patients were diagnosed as definitive PJP by
positive sputum/BAL cytology. Among patients with a defin-
itive diagnosis, two patients were excluded because of
concurrent opportunistic infections, and two patients with
evidences of pulmonary bacterial infection. Among the
other 203 patients, 76 with pulmonary bacterial infection,
55 patients without HRCTscan, 10with positive sputum acid-
fast stains, 3 with presumed pulmonary cytomegalovirus
(CMV) infections, and one with pulmonary Kaposi’s sarcoma,
were excluded. Overall, HRCT scans of 58 patients were
reviewed by a radiologist, and 12 patients were excluded for
absence of typical radiological evidence on HRCT scans.
Therefore, only 44 patients were considered as presumptive
cases of PJP. Clinical information of 41 and 44 patients with
definitive and presumptive cases of PJP, respectively, were
abstracted from their medical records.
Demographic data
In this retrospective study, 85 HIV-infected patients diag-
nosed with P jirovecii pneumonia were enrolled, and the
clinical characteristics are shown in Table 1. The mean age
(standard deviation) at the time of diagnosis was
37.64  10.15 years (range, 23e76 years), and the majority
was men (96.5%). Thirty-four patients (40%) had history of
tobacco use. While the main risk factor for HIV infection
was being a man who has sex with other men (58 patients,
68.2%), injection drug use was not so common (5 patients,
5.9%). HIV was newly diagnosed during evaluation for PJP in
66 patients (77.6%). While high risk of opportunistic infec-
tion exposures, only three patients (3.5%) were taking
HAART and four patients (4.7%) were taking PJP prophylaxis
before admission (Table 1). Four patients had previously
received HAART, but had discontinued it more than 6
months before presentation.
Clinical and laboratory data
Only 24 of 85 patients had a body temperature greater than
38C at presentation. Despite the hematocrit and leukocyte
counts were mostly within normal range, lymphopenia was
common (69 of 85, 81.2%) at the time of admission. The
mean total lymphocyte counts were 600  455 cells/mL.
Patients were severely immunosuppressed at presentation,
whereas the mean CD4 cell counts were 26.24  34.8 cells/
mL. Malnutrition status was considered at admission with
the mean serum total protein level 6.35  0.98 mg/dL and
serum albumin level 2.65  0.55 g/dL (Table 1).
Predictors of mortality
The overall mortality was 37.7% (32 of 85 patients). The
independent sample t test results of all variables atpresentation showed that there were several variables had
a significant difference (p < 0.05) in the mortality and
survival group. The variables include age, prior pulmonary
diseases, systolic blood pressure (SBP), diastolic blood
pressure, partial pressure of oxygen in arterial blood,
percentage of lymphocyte, percentage of CD4 lymphocyte,
CD4 counts, serum total protein, serum albumin, and blood
urea nitrogen (Table 2).
Univariate analyses to determine clinical variables asso-
ciated with mortality found that age more than 40 years
[odds ratio (OR) 4.33, 95% confidence interval (CI)
1.66e11.31, pZ 0.003], SBP less than 110 mmHg (OR 5.91,
95% CI 2.24e15.56, p < 0.001), diastolic blood pressure less
than 60mmHg (OR 3.34, 95%CI 1.26e8.92, pZ 0.02), PaO2 at
room air less than 60 mmHg (OR 5.63, 95% CI 1.62e18.74,
p Z 0.001), percentage of lymphocytes less than 10% (OR
3.08, 95% CI 1.08e7.81, p Z 0.04), CD4 counts less than
50 cells/mL (OR 4.96, 95% CI 1.04e23.73, p Z 0.04), serum
total protein level less than 6 g/dL (OR 3.78, 95% CI
1.29e9.85, pZ 0.01), serum albumin level less than 3 g/dL
(OR 3.40, 95% CI 1.03e11.26, p Z 0.04), and serum blood
urea nitrogen level more than 10 mg/dL (OR 3.35, 95% CI
1.33e8.48, p Z 0.01) predicted increased mortality. Other
variables such as prior pulmonary diseases, newly diagnosed
HIV infection or not, hematocrit percentage, HIV viral RNA
levels, serum total bilirubin level, and serumcreatinine level
were not associated with mortality (Table 3).
Multivariate analysis using forward stepwise regression
was performed and demonstrated three independent
predictors that were associated with mortality (Table 3),
which included SBP 110 mmHg [adjusted odds ratio (AOR)
3.88; 95% CI 1.17e12.83; p Z 0.03], PaO2 at room air
60 mmHg (AOR 4.97; 95% CI 1.34e18.23; p Z 0.01), and
lymphocytes 10% (AOR 8.19; 95% CI 1.48e45.36;
p Z 0.02).Discussion
P jirovecii is a ubiquitous organism that is classified as
a fungus, but that also shares biologic characteristics with
protozoa.4 PJP is a major cause of morbidity and mortality
among immunocompromised persons, and it remains
a leading opportunistic infection in HIV-infected
patients.2,14e16 Approximately 90% of PJP cases occurred
among patients with CD4 counts <200 cells/mL. Other
factors associated with risks for PJP included CD4 cell
percentage <14%, previous episodes of PJP, oral thrush,
recurrent bacterial pneumonia, unintentional weight loss,
and higher plasma HIV RNA.4,17,18
In this single-center retrospective study of HIV-infected
patients with confirmed or presumptive PJP, 85 patients
were enrolled. In previous reports, the mortality of HIV-
infected patients with PJP before the widespread use of
primary PJP prophylaxis and HAART was up to 70e80%, and
decreased to 11.3e53% in the HAART era.1,5e9,19 Our study
presented the overall mortality of 37.7%, which was cor-
responding to previous reports.
The mean age of our patients was 37.64  10.15 years,
and the majority was male (96.5%). The major risk factor of
HIV infection was men having sex with men (58 of 85
patients, 68.2%). All these characteristics were similar to
Table 1 Characteristics of 85 HIV-infected patients with Pneumocystis pneumonia at illness presentation at Mackay Memorial
Hospital, 1997e2009
Characteristics All cases (%)a Definitive cases (%)
n Z 85 n Z 41
Sociodemographic
Mean age, yr 37.64  10.15 38.37  9.48
Male gender 82 (96.5) 40 (97.6)
History of tobacco use 34 (40) 13 (31.7)
Medical history
HIV risk factor
MSM/bisexual males 58 (68.2) 32 (78.1)
History of injection drug use 5 (5.9) 2 (4.8)
Heterosexual 22 (25.9) 7 (18.1)
New diagnosis of HIV 66 (77.6) 28 (68.3)
Prior pulmonary diseases 6 (7.1) 4 (9.8)
HAART before admission 3 (3.5) 2 (4.8)
PJP prophylaxis 4 (4.7) 3 (7.3)
Vital signs
Mean temperature, C 37.38  1.06 37.39  0.95
Mean systolic blood pressure, mmHg 113.04  15.27 113.93  15.17
Mean diastolic blood pressure, mmHg 67.76  11.01 66.73  11.03
Mean PaO2 at room air, mmHg (n Z 71) 71.13  19.67 68.55  17.77
Mean respiratory rare, breaths/min 24.12  4.50 23.95  3.45
Laboratory data, mean values
Hematocrit, % 34.41  5.01 34.34  4.78
Leukocyte counts, cells/mL 7,660  4,223 8,291  4,879
Total lymphocyte count, cells/mL (n Z 83) 600  455 608  438
CD4 cell count, cells/mL (n Z 82) 26.24  34.80 22.30  23.71
HIV viral load, copies/mL (n Z 69) 433,349  372,957 394,937  370,886
Total protein, g/dL (n Z 82) 6.35  0.98 6.22  1.08
Albumin, g/dL (n Z 84) 2.65  0.55 2.59  0.58
Total bilirubin, mg/dL (n Z 82) 0.53  0.33 0.55  0.30
GOT, IU/L 54.73  72.11 62.93  96.23
GPT, IU/L 31.74  35.99 34.37  46.06
BUN, mg/dL 11.62  7.23 11.42  5.68
Creatinine, mg/dL 0.89  0.29 0.87  0.20
Sodium, mEq/L 136.84  3.44 136.20  3.44
Potassium, mEq/L 4.21  0.53 4.24  0.52
a Values are shown as n (%) or mean (standard deviation).
BUNZ blood urea nitrogen; GOTZ glutamic oxaloacetic transaminase; GPTZ glutamic pyruvic transaminase; HAART Z highly active
antiretroviral therapy; HIV Z human immunodeficiency virus; MSM Z man who has sex with other men; PaO2 Z partial pressure of
oxygen in arterial blood; PJP Z Pneumocystis jirovecii pneumonia.
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same period.20,21 However, the injecting drug users (IDUs)
account for five of our patients (5.9%), which was remark-
able less than the general distribution (21.5%e32.0%).20,21
The most important risk factor for Taiwanese IDUs was
needle sharing, followed by the sharing of heroin diluents.
In our study, the lower IDUs rate compared with general
distribution may contribute to two-thirds of Taiwan’s IDUs
living in central and southern parts.22
In our study, most patients were newly diagnosed of HIV
infection during evaluation for PJP (66 of 85 patients,
77.6%), which result in small proportion of PJP prophylaxisand HAART (4.7% and 3.5%, respectively) at admission. Poor
compliance was observed in four patients who discontinued
HAART more than 6 months. In previous studies, HIV was
newly diagnosed on PJP patients between 23 and
69%.3,5,6,10,11 The higher rate of newly diagnosed HIV
infection in our study may result from many signs of
persistent denial and discrimination in Taiwan.22 However,
lack of recognition may lead to delayed diagnosis, delayed
treatment, and higher mortality.23,24
Based on the multivariate analysis results, we identified
three independent predictors, which were associated with
mortality, including SBP 110 mmHg, PaO2 at room air
Table 2 Independent sample t test analysis of characteristics associated with mortality in 85 HIV-infected patients with
Pneumocystis jirovecii pneumonia
Characteristics All cases Definitive cases
Died (n Z 32) Survived (n Z 53) p Died (n Z 18) Survived (n Z 23) p
Sociodemographic
Mean age 41.44 35.34 0.02 40.11 37.00 0.32
Male 31 51 0.88 17 23 0.25
MSM/bisexual males 20 38 0.34 13 19 0.43
Recent illicit or injection drug use 1 4 0.40 1 1 0.85
Tobacco use 10 24 0.20 6 7 0.84
Medical history
New diagnosis of HIV 24 42 0.65 15 13 0.07
Prior pulmonary diseases 5 1 0.02 3 1 0.19
HAART before admission 2 1 0.29 1 1 0.85
PJP prophylaxis 2 2 0.60 1 2 0.70
Vital signs, mean values
Temperature, C 37.55 37.28 0.31 37.63 37.20 0.15
SBP, mmHg 105.63 117.51 0.001 103.78 121.87 <0.001
DBP, mmHg 63.69 70.23 0.007 61.67 70.70 0.008
Respiratory rare, breaths/min 24.94 23.62 0.19 24.44 23.57 0.44
PaO2 at room air, mmHg (n Z 71) 59.90 77.61 0.001 59.42 75.20 0.005
Laboratory data, mean values
Hematocrit, % 33.98 34.67 0.54 34.10 34.53 0.78
Leukocyte count, cells/mL 8,794 6,975 0.05 9,508 6,556 0.05
Percentage of lymphocyte, % 6.19 11.08 0.003 4.50 12.18 <0.001
Lymphocyte count, cells/mL 497.22 664.27 0.09 438.20 741.58 0.03
Percentage of CD4 T cell, % 3.25 4.89 0.06 1.98 3.90 0.007
CD4 T-cell count, cells/mL 14.52 33.36 0.004 11.87 30.47 0.01
Percentage of CD8 T cell, % 53.58 52.60 0.75 51.48 55.62 0.31
CD8 T-cell count, cells/mL 280.76 365.13 0.21 237.92 441.70 0.05
Platelet count, cells/mL 248,296 259,957 0.70 287,333 294,150 0.87
Viral load, copies/mL 366,704 462,506 0.33 305,902 441,391 0.27
Glucose, mg/dL 113.34 103.77 0.19 117.67 107.09 0.41
Total protein, g/dL 5.90 6.63 0.001 5.58 6.73 <0.001
Albumin, g/dL 2.43 2.79 0.003 2.27 2.84 0.001
Total bilirubin, mg/dL 0.58 0.50 0.31 0.58 0.53 0.58
GOT, IU/L 76.63 41.51 0.08 91.89 40.26 0.09
GPT, IU/L 42.91 25.00 0.07 49.00 22.91 0.07
Total cholesterol, mg/dL 133.69 130.67 0.70 129.50 131.87 0.86
BUN, mg/dL 14.53 9.87 0.01 13.22 10.00 0.08
Creatinine, mg/dL 0.96 0.85 0.13 0.91 0.84 0.30
Sodium, mEq/L 136.69 136.92 0.76 136.06 136.30 0.82
Potassium, mEq/L 4.15 4.25 0.37 4.13 4.33 0.23
BUN Z blood urea nitrogen; DBP Z diastolic blood pressure; GOT Z glutamic oxaloacetic transaminase; GPT Z glutamic pyruvic
transaminase; HAARTZ highly active antiretroviral therapy; HIVZ human immunodeficiency virus; MSMZ man who has sex with other
men; PaO2 Z partial pressure of oxygen in arterial blood; PJP Z Pneumocystis jirovecii pneumonia; SBP Z systolic blood pressure.
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presence of underlying medical comorbidities and general
severity of illness, the PaO2 level represented respiratory
condition from PJP, and the percentage of lymphocyte was
associated with the severity of underlying HIV disease. The
mortality ranged from 14% (one predictor), 47% (any two
predictors) to 75% (all three predictors). We can easily
classify patients by their existing predictors, and aware
their possible deterioration. Clinical improvement wasobserved on patients with severe PJP from intensive care
unit care without HAART intervention,6 therefore we can
refer patients to intensive care unit earlier if patients were
classified as high risk of mortality by this predicting rule.
Meanwhile, better HIV control may contribute to decline
mortality and suppress diseases progression.4,25,26
To our knowledge, there were no previous studies that
demonstrate the associations between SBP and the
percentage of lymphocyte with increased PJP mortality.
Table 3 Characteristics associated with mortality in univariate and multivariate analyses in 85 HIV-infected patients with
Pneumocystis jirovecii pneumonia
Univariate predictors Unadjusted odds ratio (95% CI), p
All cases (n Z 85) Definitive cases (n Z 41)
Aged more than 40 yr 4.33 (1.66e11.31), 0.003 d
Prior pulmonary diseases 9.44 (1.05e84.99), 0.05 d
Systolic blood pressure 110 mmHg 5.91 (2.24e15.56), <0.001 16.63 (3.54e78.0), 0.003
Diastolic blood pressure 60 mmHg 3.34 (1.26e8.92), 0.02 5.94 (1.43e24.66), 0.01
PaO2 at room air 60 mmHg (n Z 71)
5.63 (1.62e18.74), 0.001
(n Z 35)
5.79 (1.34e25.07), 0.02
Percentage of lymphocytes 10% 3.08 (1.08e8.72), 0.04 7.46 (1.78e31.36), 0.01
Total lymphocyte count 500 cells/mL e 2.6 (0.72e9.36), 0.04
Percentage of CD4 T cell 5% e 13.08 (1.48e11.52), 0.02
CD4 T-cell counts 50 cells/mL (n Z 82)
4.96 (1.04e23.73), 0.04
(n Z 40)
5.46 (1.24e24.09), 0.03
Serum total protein level 6 g/dL (n Z 82)
3.78 (1.29e9.85), 0.01
(n Z 40)
7.37 (1.84e29.55), 0.005
Serum albumin level 3 g/dL (n Z 84)
3.40 (1.03e11.26), 0.04
(n Z 41)
4.88 (1.27e18.65), 0.02
Serum BUN level 10 mg/dL 3.35 (1.33e8.48), 0.01 e
Multivariate predictors (forward stepwise: R)
Systolic blood pressure 110 mmHg 3.88 (1.17e12.83), 0.03 15.63 (1.90e25.37), 0.01
PaO2 at room air 60 mmHg 4.97 (1.34e18.23), 0.01 d
Percentage of lymphocytes 10% 8.19 (1.48e45.36), 0.02 10.99 (1.19e17.82), 0.04
BUN Z blood urea nitrogen; CI Z confidence interval; HIV Z human immunodeficiency virus; PaO2 Z partial pressure of oxygen in
arterial blood.
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pressor use as a mortality predictor on HIV-infected PJP
patients, which would be a late phenomenon of sepsis,
leading organ failure and mortality.11,12 Use of SBP alone as
a predictor could recognize the risk factor earlier and avoid
further deterioration. There were reports identified lower
total leukocyte counts and CD4 T-cell counts at admission
as predictors of HIV disease progression, and increase
mortality on HIV-infected patients with PJP.12,27 However,
the percentage of lymphocyte is far more meaningful than
total leukocyte count to determine the severity of under-
lying HIV disease. Therefore our predictors not only detect
the risk of mortality earlier than other predicting models,
but also reflect the real severity of respiratory condition
and immune status.
Despite PJP remains the leading opportunistic infection in
HIV-infected patients and causes nonspecific pulmonary
symptoms and hypoxia,2,4 bacterial pneumonia, pulmonary
TB, and CMV pneumonitis are common and their manifesta-
tions may by atypical.4,28 In developing world such as India,
reports showed the most common opportunistic infection in
HIV-infected patients was pulmonary TB, followed by
bacterial pneumonia and CMV infection.29e31 In Taiwan,
Tang et al.32 studied 15 AIDS patients with autopsy, in which
six patients diagnosed premortem with PJP, but only one
confirmed by postmortem pathological findings, and six of
eight patients diagnosed as CMV infection at postmortem
examination did not have premortem presumption. The
substantial discrepancies between premortem clinical
diagnosis and autopsy findings are worth attention,especially CMV infection. Collins et al. mentioned that in
patients with AIDS and CMV pneumonia, CT scanning will
show diffuse pattern of ground-glass opacity, dense consol-
idation, bronchial wall thickening or bronchiectasis, and
interstitial reticulation without air-space disease, and the
presence of an isolated ground-glass infiltrate without
additional findings in patients with AIDS is highly suggestive
of PJP.33
In our study, the confirmation of PJP was mainly from
BAL and induced sputum samples, which are frequently
used for the investigation of PJP with good sensitivity
(50e90% and 90e99%, respectively). Despite open lung
biopsy is considered as a gold standard with better sensi-
tivity (95e100%), it is rarely performed in the current
clinical practice.4,14,34 The routine cytological staining
techniques (Giemsa, Papanicolaou, and Grocott’s methe-
namine silver nitrate) are used before, but specialized
techniques such as immunocytochemistry and polymerase
chain reaction are more promising and recommended
currently.2,34,35
This study had several limitations. First, it was retro-
spective and from a single center. As not an observational
cohort study, some clinically significant differences might
not being detected. Different population or different
hospitals could be expected to have different results.
Second, it included not only patients with laboratory-
proven PJP, but also patients with presumptive PJP in the
earlier period, which might be diagnosed as other pulmo-
nary opportunistic infection or coinfection eventually.32
Third, it examined mortality risk factors present at or
280 H.-W. Wang et al.soon after hospital admission, which would be days or even
weeks before PJP diagnosed. Some patients would not be
enrolled to this study if they were too severe to confirm the
diagnosis. Next, we did not follow patients after hospital
discharge, therefore the predictors of long-term mortality
and any impact of HAART on long-term survival remain
unknown. Large, prospective studies would be needed to
determine the predicting factors of mortality from HIV-
infected patient with PJP at presentation.
In summary, the overall mortality from HIV-infected
patients with PJP patient at this medical center over the
15-year period of this study was 37.7%. In multivariate
analysis, we identified three clinical and laboratory data,
including SBP, PaO2, and percentage of lymphocyte, as
predictors of mortality from HIV-infected patients with PJP
at presentation. These predictors were easily obtained at
patient’s admission to hospital, and a higher mortality rate
was observed when more predictors were present. Although
this prediction rule requires further validation in cohorts, it
is likely a practical method to stratify patients by risk for in-
hospital mortality, and therefore may assist clinicians to
take accurate strategies for better care and outcomes of
HIV-infected patients with PJP.
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